AMENDMENTS TO THE CLAIMS

1. (canceled)

2. (currently amended) The compound of claim ~~1~~ 23 wherein

Z_P is 1,1-dimethylethyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, ~~1-hydroxy-2,2-dimethylpropyl, or 1-hydroxy-1,2,2-trimethylpropyl, provided that (L_1), (L_2), (L_3) are all bonds~~;

Z_F is selected from:

-C(O)NHMe,
-C(O)NHEt,
-C(O)NHOMe,
-C(O)NHOEt,
-C(O)NH(iPr),
-C(O)NH(tBu),
-C(O)NH(CF_3),
-C(O)N$(Me)_2$,
-C(O)NMeEt,
-C(O)NMe(iPr),
-C(O)NMe(tBu),
-C(O)NMe(CF_3),
~~-C(O)N(Me)F,~~
~~-C(O)N(Et)F~~
~~-C(O)N(iPr)F,~~
~~-C(O)N(tBu)F,~~
-C(O)N$(Et)_2$, or
-C(O)NEt(iPr);

or a pharmaceutically acceptable salt thereof.

3. (previously presented) The compound of claim 2 wherein

Z_F is selected from:

-C(O)NHMe,
-C(O)NHEt,

-C(O)NH(iPr),
-C(O)NH(tBu),
-$C(O)N(Me)_2$,
-C(O)NMeEt,
-C(O)NMe(iPr),
-C(O)NMe(tBu),
-$C(O)N(Et)_2$, or
-C(O)NEt(iPr);

or a pharmaceutically acceptable salt thereof.

4. (currently amended) A compound according to claim ~~1~~23, or a pharmaceutically acceptable salt ~~or ester prodrug derivative~~ thereof, represented by formulae A to J as follows:

A)


,

B)


,

C)


,

E)



,

F)



,

G)



,

H)



,

I)



,

J)



, and

K)



.

5. (canceled)

6. (currently amended) A pharmaceutical formulation comprising the compound of claim ~~1~~23 together with a pharmaceutically acceptable carrier or diluent.

7-10. (canceled)

11. (withdrawn, currently amended) A method of treating a mammal to prevent or alleviate the pathological effects of ~~Acne, Actinic keratosis, Alopecia , Alzheimer's disease, Bone maintenance in zero gravity, Bone fracture healing, Breast cancer, Chemoprevention of Cancer, Crohn's disease, Colon cancer, Type I diabetes, Host-graft rejection, Hypercalcemia , Type II diabetes, Leukemia, Multiple sclerosis, Myelodysplastic syndrome, Insufficient sebum secretion, Osteomalacia,~~ Osteoporosis or~~,~~ ~~Insufficient dermal firmness, Insufficient dermal hydration, Psoriatic arthritis, Prostate cancer,~~ Psoriasis~~, Renal osteodystrophy, Rheumatoid arthritis, Scleroderma, Skin cancer, Systemic lupus erythematosus, Skin cell damage from Mustard vesicants, Ulcerative colitis, Vitiligo, or Wrinkles;~~ wherein the method comprises administering a pharmaceutically effective amount of at least one compound of claim ~~1~~23.

12. (withdrawn) The method of claim 11 for the treatment of psoriasis.

13. (withdrawn) The method of claim 11 for the treatment of osteoporosis.

14-15. (canceled)

16. (withdrawn, currently amended) The method of treating ~~or preventing~~ disease states mediated by the Vitamin D receptor, wherein a mammal in need thereof is administered a pharmaceutically effective amount of a compound of Claim ~~1~~23.

17-22. (canceled)

23. (new) A compound represented by a formula below or a pharmaceutically acceptable salt derivative thereof:



wherein;

R and R' are independently C_1-C_4 alkyl;

R_P, $R_{P'}$, and R_F are independently selected from the group consisting of hydrogen and C_1-C_4 alkyl;

(L_1) is oxygen;

(L_2) is $-C(R40)_2-$, where each R40 is independently hydrogen, C_1-C_5 alkyl or C_1-C_5 fluoroalkyl;

(L_3) is $-C(=X_1)-$, where X_1 is O, S, CH_2, or [H,OH];

(L_F) a bond;

Z_F is



where R4 and R5 are independent hydrogen, C_1-C_4 alkyl, -O-C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_1-C_4 haloalkyl, -NH(C_1-C_4 alkyl), or cyclopropyl, with the proviso that only one of R4 or R5 may be hydrogen;

Z_P is

methyl,
ethyl,
n-propyl,
1-methylethyl,
1-methylpropyl,
2-methylpropyl,
1,1-dimethylethyl,
1,1-dimethylpropyl,
1,2-dimethylpropyl, or
2,2-dimethylpropyl.